معرفی
Dr. Shumaila Shad serves as an Affiliate within the Clinical Trials Unit of the School of Cancer Sciences at the University of Glasgow, focusing on translational oncology research with dual specialization in neuro-oncology and thoracic malignancies.
Her research portfolio spans:
- Neuro-oncology: Phase I trials optimizing PARP inhibitor-radiotherapy combinations for elderly glioblastoma patients
- Thoracic oncology: Diagnostic innovation in lung cancer staging using minimally invasive thoracoscopy
- Clinical trial methodology: Multicentre observational and interventional study design
- Vulnerable populations: Treatment adaptation for elderly and complex-stage cancer patients
Recent publications (2023-2024) demonstrate active leadership in high-impact clinical trials, with the PARADIGM study addressing critical treatment gaps in elderly glioblastoma and the STRATIFY protocol establishing new standards for lung cancer staging. Her work emphasizes practical implementation within NHS infrastructure.
As part of the University of Glasgow's Clinical Trials Unit, Dr. Shad leverages:
- Integrated NHS Scotland cancer network access
- Wolfson Wohl Cancer Research Centre translational facilities
- Multidisciplinary collaboration with radiation oncologists and thoracic surgeons
- Centralized trial management infrastructure for complex protocols
۰مقاله منتشرشده
